JP2011519868A - 癌を処置するための化学療法剤の連続投与 - Google Patents

癌を処置するための化学療法剤の連続投与 Download PDF

Info

Publication number
JP2011519868A
JP2011519868A JP2011507707A JP2011507707A JP2011519868A JP 2011519868 A JP2011519868 A JP 2011519868A JP 2011507707 A JP2011507707 A JP 2011507707A JP 2011507707 A JP2011507707 A JP 2011507707A JP 2011519868 A JP2011519868 A JP 2011519868A
Authority
JP
Japan
Prior art keywords
antibody
cancer
inhibitor
subject
igf1r
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011507707A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011519868A5 (enExample
Inventor
ヤオリン ワン，
ヤン ワン，
ブライアン デル−ファ ルー，
ミン リュー，
シンシア シーデル−デュガン，
シュー−ロン ヤオ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2011519868A publication Critical patent/JP2011519868A/ja
Publication of JP2011519868A5 publication Critical patent/JP2011519868A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011507707A 2008-05-05 2009-05-04 癌を処置するための化学療法剤の連続投与 Withdrawn JP2011519868A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5040508P 2008-05-05 2008-05-05
US61/050,405 2008-05-05
PCT/US2009/042657 WO2009137378A2 (en) 2008-05-05 2009-05-04 Sequential administration of chemotherapeutic agents for treatment of cancer

Publications (2)

Publication Number Publication Date
JP2011519868A true JP2011519868A (ja) 2011-07-14
JP2011519868A5 JP2011519868A5 (enExample) 2012-06-07

Family

ID=40940448

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011507707A Withdrawn JP2011519868A (ja) 2008-05-05 2009-05-04 癌を処置するための化学療法剤の連続投与

Country Status (6)

Country Link
US (1) US20110129456A1 (enExample)
EP (1) EP2282739A2 (enExample)
JP (1) JP2011519868A (enExample)
CA (1) CA2722992A1 (enExample)
MX (1) MX2010012064A (enExample)
WO (1) WO2009137378A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018533582A (ja) * 2015-10-30 2018-11-15 カリセラ バイオサイエンシズ，インコーポレイテッド アルギナーゼ活性を阻害する組成物及び方法
US11389464B2 (en) 2010-10-26 2022-07-19 Mars, Incorporated Arginase inhibitors as therapeutics
US12054501B2 (en) 2016-12-22 2024-08-06 Precision Pharmaceuticals, Inc. Compositions and methods for inhibiting arginase activity

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
EP3488866A1 (en) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
EP2102230A2 (en) 2006-12-29 2009-09-23 Gloucester Pharmaceuticals, Inc. Purifiction of romidepsin
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
MX2010010480A (es) * 2008-03-25 2010-10-15 Schering Corp Metodos de tratamiento o prevencion del cancer colorrectal.
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
EP3175853B1 (en) 2008-08-04 2023-11-01 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
UY32317A (es) 2008-12-12 2010-07-30 Boehringer Ingelheim Int Anticuerpos anti-igf
PT3000467T (pt) 2009-04-06 2023-03-30 Wyeth Llc Regime de tratamento utilizando neratinib para o cancro de mama
CN102781316B (zh) * 2010-03-01 2016-07-06 陶制药有限责任公司 癌症诊断和成像
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
WO2012068339A2 (en) * 2010-11-17 2012-05-24 Glaxosmithkline Llc Methods of treating cancer
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
WO2012112847A1 (en) * 2011-02-18 2012-08-23 Novartis Pharma Ag mTOR/JAK INHIBITOR COMBINATION THERAPY
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
JP6309610B2 (ja) 2013-03-14 2018-04-11 アブラクシス バイオサイエンス， エルエルシー 膀胱がんを処置する方法
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
BR112016022056B1 (pt) 2014-03-26 2023-04-11 Astex Therapeutics Limited Combinação, composição farmacêutica, uso de uma combinação ou uma composição farmacêutica, e, produto farmacêutico
US10736900B2 (en) * 2014-03-26 2020-08-11 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
EP3148532B1 (en) 2014-05-28 2021-03-03 Piramal Enterprises Limited Pharmaceutical combination comprising a cdk inhibitor and a thioredoxin reductase inhibitor for the treatment of cancer
CN106999734B (zh) * 2014-09-29 2020-06-16 得克萨斯大学体系董事会 针对parp抑制剂的应答的预测和靶向c-met和parp1的组合疗法
HUE054012T2 (hu) 2014-10-29 2021-08-30 Five Prime Therapeutics Inc Kombinációs terápia rák ellen
KR102309882B1 (ko) * 2014-11-21 2021-10-06 삼성전자주식회사 c-Met 저해제 및 IGF-1R 저해제를 포함하는 병용 투여용 약학 조성물
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CA2980460A1 (en) 2015-04-13 2016-10-20 Five Prime Therapeutics, Inc. Combination therapy for cancer
WO2017050865A1 (en) 2015-09-23 2017-03-30 Janssen Pharmaceutica Nv Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
HUE050567T2 (hu) 2015-09-23 2020-12-28 Janssen Pharmaceutica Nv Triciklusos heterociklusok rák kezelésére
BR112018008882A8 (pt) * 2015-11-03 2019-02-26 Univ Texas método para tratar um distúrbio proliferativo e produto farmacêutico
CA3059593A1 (en) * 2017-05-21 2018-11-29 Igf Oncology, Llc An insulin-like growth factor-chemotherapeputic conjugate for treating myelodysplastic syndrome
JP2020535119A (ja) 2017-09-13 2020-12-03 ファイヴ プライム セラピューティクス インク 膵臓がんの抗ｃｓｆ１ｒおよび抗ｐｄ−１抗体組合せ併用療法
CN113684180B (zh) * 2021-08-31 2023-05-26 山东大学第二医院 一种提高骨髓瘤杀伤活性的nk细胞制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119069A0 (en) * 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
MXPA04011624A (es) * 2002-05-24 2005-03-07 Schering Corp Anticuerpo neutralizante humano anti-igfr.
EP2365001A3 (en) * 2003-05-01 2012-03-28 Imclone LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
CN1835975B (zh) * 2003-08-13 2012-11-21 辉瑞产品公司 经修饰的人类igf-1r抗体
AR046639A1 (es) * 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
CN101222926B (zh) * 2005-04-15 2013-07-17 默沙东公司 用于治疗或预防癌症的方法和组合物
WO2008079849A2 (en) * 2006-12-22 2008-07-03 Genentech, Inc. Antibodies to insulin-like growth factor receptor

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11389464B2 (en) 2010-10-26 2022-07-19 Mars, Incorporated Arginase inhibitors as therapeutics
JP2018533582A (ja) * 2015-10-30 2018-11-15 カリセラ バイオサイエンシズ，インコーポレイテッド アルギナーゼ活性を阻害する組成物及び方法
US12054501B2 (en) 2016-12-22 2024-08-06 Precision Pharmaceuticals, Inc. Compositions and methods for inhibiting arginase activity

Also Published As

Publication number Publication date
MX2010012064A (es) 2010-12-06
EP2282739A2 (en) 2011-02-16
CA2722992A1 (en) 2009-11-12
US20110129456A1 (en) 2011-06-02
WO2009137378A3 (en) 2010-03-04
WO2009137378A2 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
US20110129456A1 (en) Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
US20110104256A1 (en) Methods for treating or preventing colorectal cancer
CN102123712B (zh) 使用igf1r抑制剂治疗癌症的方法
US8216571B2 (en) Fully human anti-VEGF antibodies and methods of using
JP5816147B2 (ja) Ｉｇｆｂｐ２インヒビター
WO2010124009A2 (en) Fully human anti-vegf antibodies and methods of using
US20110014117A1 (en) Anti-igf1r
US20100143340A1 (en) Methods and compositions for treating cancer
US20150093398A1 (en) Methods and Compositions for Treating or Preventing Cancer
CN101287761A (zh) 抗-igf1r抗体制剂
TW202515912A (zh) 抗-egfr抗體及抗體藥物結合物
WO2011057064A1 (en) Igf1r inhibitor based treatment of prostate cancer
BRPI0720924A2 (pt) Métodos de tratamento

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120418

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20130812